临床荟萃

• 专题 • 上一篇    下一篇

2017年风湿免疫病主要临床进展

  

  1. 河北医科大学第二医院 风湿免疫科, 河北 石家庄  050000
  • 出版日期:2018-01-05 发布日期:2018-01-22
  • 通讯作者: 通信作者:郭惠芳, Email :guohfch@ 126.com
  • 作者简介:高丽霞,女,河北医科大学第二医院风湿免疫科主任医师,医学博士,硕士生导师。中华医学会风湿病学分会第九届青年委员,河北省免疫学会风湿免疫专业委员会委员,河北省医师协会风湿病分会委员,河北省免疫吸附学组委员。长期从事风湿病学临床、科研和教学工作,曾在国内外专业杂志上发表SCI、核心期刊文章共40余篇,独立承担省级厅级科研项目5项,获省科技进步奖等科技成果奖3项。

Major advances in clinical research of rheumatic diseases of 2017

  1. Department of Rheumatology and Immunology,  the Second Hospital of Hebei Medical University,   Shijiazhuang 050000,  China
  • Online:2018-01-05 Published:2018-01-22
  • Contact: Corresponding author: Guo Huifang, Email: guohfch@ 126.com

摘要: 2017年系统性红斑狼疮、特发性炎症性肌病和ANCA相关性血管炎的诊断标准再次更新, 类风湿关节炎、干燥综合征、脊柱关节炎以及痛风等多个管理指南相继出台,并且不断细化。抗风湿药物的使用规范越来越详细,糖皮质激素、非甾体抗炎药的不良反应也引起了高度关注,并推出了国内专家共识。风湿病的诊治策略越来越丰富,管理越来越规范。

关键词: 风湿病, 红斑狼疮, 系统性, 关节炎, 类风湿, 干燥综合征, 药物, 治疗策略

Abstract: In 2017, the diagnostic criteria of systemic lupus erythematosus,idiopathic inflammatory myopathies and antineutrophil cytoplasmic antibody associated vasculitis have been renewed. Multiple management guidelines, for example rheumatoid arthritis, Sjogren's syndrome spondyloarthritis and gout etc, have been published and refined. The use of antirheumatic drugs become more and more detailed, and the adverse reaction of glucocorticoid and nonsteroidal antiinflammatory drugs has also aroused great concern. And then, domestic expert consensus have been introduced. The diagnosis and treatment strategy of rheumatic diseases become more and more abundant, and the management methods also become more and more standard.

Key words: rheumatic disease, lupus erythematosus, arthritis, rheumatoid, Sjgren’s syndrome, drug;treatment strategy